IPSCHealthcare · BiotechnologyThe 5 Wall Street analysts covering Century Therapeutics, Inc. hold a median 12-month price target of $4.5 — +200.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 28 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Century Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (87): The shares have been drifting up relative to others.
Growth (10): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on IPSC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +200.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 May 2026 | Mizuho | Initiates | Outperform | $8.00 |
| 21 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 Jan 2026 | Piper Sandler | Maintains | Overweight | — |
| 17 Nov 2025 | Leerink Partners | Downgrade | Market Perform | — |
| 16 May 2025 | Chardan Capital | Maintains | Buy | — |
| 3 Apr 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Mar 2025 | Guggenheim | Reiterates | Buy | — |
| 24 Mar 2025 | Chardan Capital | Maintains | Buy | — |
| 21 Mar 2025 | Guggenheim | Maintains | Buy | — |
| 20 Mar 2025 | Piper Sandler | Maintains | Overweight | — |
| 22 Jan 2025 | Guggenheim | Reiterates | Buy | — |
| 22 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Dec 2024 | Piper Sandler | Maintains | Overweight | — |
| 7 Nov 2024 | Chardan Capital | Maintains | Buy | — |
| 6 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 June 2024 | Piper Sandler | Maintains | Overweight | — |
| 4 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Apr 2024 | Piper Sandler | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
IPSC appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, Century Therapeutics, Inc. returned +141.9% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 94% of US stocks
Cheaper than 47% of US stocks
Cheaper than 67% of US stocks
Cheaper than 73% of US stocks
Higher than 1% of US stocks
Higher than 24% of US stocks
Higher than 30% of US stocks
Higher than 21% of US stocks
Higher than 17% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Century Therapeutics, Inc. has a market value of $271.6M and an enterprise value of $190.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$109.8M.
Free cash flow in the twelve months to 30 June 2026: −$88.1M.
Trailing P/E: −10.7×; forward P/E: −3.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Century Therapeutics, Inc. employs 78 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Century Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Century Therapeutics announced that it will attend the 2026 Jefferies Global Healthcare Conference in London on November 18, 2026.
Why it matters — The conference appearance is a company event relevant to investors following Century Therapeutics and its cell-therapy programs.
Century Therapeutics presented nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at EASD 2026. The data demonstrated scalable production, in vivo function, immune evasion, and updated progress toward clinical dosing.
Why it matters — This marks continued advancement of Century's iPSC-based diabetes candidate toward the clinic, showing progress on key development milestones for the company's pipeline.
Century Therapeutics, rated speculative Buy with a $363M equity value, focuses on CNTY-813 for type 1 diabetes, which aims to deliver insulin-producing islets without chronic systemic immunosuppression using Allo-Evasion 5.0 genetic edits. Strong preclinical results and a cash runway into Q1 2029 support the risk/reward, though lack of human data and potential dilution keep conviction low.
Why it matters — IPSC watchers would care because the outlook for its lead CNTY-813 program hinges on whether preclinical promise translates to human data, with cash runway into 2029 and dilution risk shaping the investment case.
Century Therapeutics announced the appointment of Joseph Truitt to its Board of Directors. The announcement was made public on September 9, 2026.
Why it matters — A new board appointment brings additional experience and governance perspective to the company as it continues developing iPSC-derived cell therapies.
Century Therapeutics reported second quarter 2026 financial results, including $197.2 million in cash with a runway into the first quarter of 2029. The company completed a pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes, with an IND submission on track for the fourth quarter of 2026, and remains on track to advance CNTY-308 into the clinic this year.
Why it matters — For IPSC watchers, the progress of CNTY-813 toward an IND, positive preclinical data, and the planned clinical advancement of CNTY-308 represent key developmental milestones for the company's iPSC-derived cell therapy pipeline.
The 5 Wall Street analysts covering Century Therapeutics, Inc. have a median 12-month price target of $4.5, with estimates ranging from $2 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Century Therapeutics, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Century Therapeutics, Inc. 44 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Century Therapeutics, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (87 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +200.0% from the last close, and Ticker Nerd's factor model ranks Century Therapeutics, Inc. 44 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Century Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IPSC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $8 over the next 12 months.
Century Therapeutics, Inc. returned +141.9% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Century Therapeutics Inc is a biotechnology company focused on developing allogeneic cell therapies for cancer, autoimmune diseases, and other immune-mediated conditions. The company uses induced pluripotent stem cell technology to create off-the-shelf immune cell products, including natural killer and T cell therapies designed to target solid tumors and hematological malignancies.
The most recent item we track (GlobeNewsWire, 14 Oct 2026): "Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London". Century Therapeutics announced that it will attend the 2026 Jefferies Global Healthcare Conference in London on November 18, 2026.
Century Therapeutics Inc is a biotechnology company focused on developing allogeneic cell therapies for cancer, autoimmune diseases, and other immune-mediated conditions. The company uses induced pluripotent stem cell technology to create off-the-shelf immune cell products, including natural killer and T cell therapies designed to target solid tumors and hematological malignancies. Its current pipeline also includes programs in type 1 diabetes and other autoimmune applications, reflecting a broader effort to apply engineered cell therapy platforms across multiple disease areas. Century Therapeutics combines stem cell derivation, gene editing, and immune-evasion technologies to support scalable manufacturing and differentiated product development. Headquartered in Philadelphia, Pennsylvania, Century Therapeutics operates in the advanced biotechnology segment of the healthcare market, where it develops next-generation cellular medicines intended for clinical use.
CEO Dr. Brent Pfeiffenberger M.B.A., Pharm.D. · 78 employees · United States · https://www.centurytx.com
